Intestinal burying of the jejunal-tube of a PEG-J levodopa-carbidopa release system for Parkinson's disease. Successful endoscopic management.

Autor: Moralejo Lozano Ó; Gastroenterology and Hepatology, Hospital Clínico San Carlos, ESPAÑA., Barrajón Masa AJ; Gastroenterology and Hepatology , Hospital Clínico San Carlos., Colmenares Bulgheroni M; Gastroenterology and Hepatology, Hospital Clínico San Carlos, España.
Jazyk: angličtina
Zdroj: Revista espanola de enfermedades digestivas [Rev Esp Enferm Dig] 2021 Mar; Vol. 113 (3), pp. 226-227.
DOI: 10.17235/reed.2020.7180/2020
Abstrakt: Levodopa-carbidopa intestinal gel (LCIG) continuous infusion into the jejunum through a percutaneous endoscopic gastrostomy with a jejunal extension (PEG-J) is an alternative therapy for Parkinson's disease (PD) patients, with a very poor control of their symptoms on regular oral medications (Hoehn-Yahr stage IV). Around 62.2 % of patients present procedure and device-related adverse effects (AE), with an 8.2 % rate of mayor complications.
Databáze: MEDLINE